Taken together, it remains open whether the potential beneficial effects of S1P2 antagonists, i.e., inhibition of mast cell degranulation, improvement of the vascular barrier, and attenuation of airway constriction, would outweigh their potential deleterious effect, i.e., aggravation of hypotension, in human anaphylaxis. The gene discussed is S1PR2; the disease is anaphylaxis.